The global PD-1 and PD-L1 Inhibitor Market Growth Accelerated by Adoption in Cancer Treatment
PD-1 and PD-L1 inhibitors are monoclonal antibodies used to treat various types of cancers including melanoma, lung cancer, renal cancer etc. PD-1 and PD-L1 inhibitors work by blocking the interaction between PD-1 and PD-L1/PD-L2, thereby activating the immune system to fight cancer. With increasing prevalence of cancer worldwide and greater acceptance of immunotherapy among oncologists, PD-1 and PD-L1 inhibitors have gained widespread adoption in cancer treatment regimen. The global PD-1 and PD-L1 Inhibitor Market is estimated to be valued at US$ 39.83 Bn in 2023 and is expected to exhibit a CAGR of 19% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The increasing adoption of PD-1 and PD-L1 inhibitors in cancer treatment is a major trend fueling market growth. As clinical evidence of benefit of PD-1 and PD-L1 inhibitors in the treatment of various cancer types accumulated over the years, immunotherapy using these agents have become a standard therapy for many late-stage cancers. Their use as monotherapy or in combination with other therapies has improved treatment outcomes for hard-to-treat cancers. This has led to rapid uptake of these drugs worldwide. Development of biomarkers to identify patients likely to respond to PD-1 and PD-L1 inhibitors is another key trend, helping enable personalized immunotherapy regimens.
Segment Analysis
The global PD-1 and PD-L1 inhibitor market is dominated by the oncology segment.PD-1 and PD-L1 inhibitors are mainly used to treat various cancers like lung cancer, skin cancer, kidney cancer, lymphoma, myeloma etc. Within oncology, lung cancer dominates as a major application area for PD-1 and PD-L1 inhibitors due to high prevalence of lung cancer worldwide.
Key Takeaways
The global PD-1 And PD-L1 Inhibitor Market Demand is expected to witness high growth over the forecast period. The North American region currently dominates the market owing to high prevalence of cancer, rising healthcare expenditure, presence of advanced healthcare infrastructure and availability of favorable reimbursement policies in the region.
Regional analysis
North America is expected to continue dominating the PD-1 and PD-L1 inhibitor market during the forecast period. This is attributed to factors such as high prevalence of cancer, rising healthcare expenditure, presence of advanced healthcare infrastructure and availability of favorable reimbursement policies in the region. Asia Pacific is expected witness the highest growthrate over the forecast period led by rapidly improving healthcare infrastructure, rising healthcare expenditure, growing awareness regarding advanced treatment options and increasing incidence of cancer in the region.
Key players
Key players operating in the PD-1 and PD-L1 inhibitor market are Super Vac, Ziamatic Corp., Akron Brass Company, Fire Hooks Unlimited, Inc., Tempest Technology Corporation, CMC Rescue, Inc., SavaTech Corp., Water Rescue Innovations, RUTH LEE Ltd., Mustang Survival, DURATEK Inc., Safety & Rescue Australia, WernerCo, Sterling Rope Company, Inc., PETZL Distribution.
For more insights, Read- http://marketerefforts.weebly.com/home/pd-1-and-pd-l1-inhibitor-market-is-estimated-to-witness-high-growth-owing-to-opportunity-for-cancer-treatment
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Russian
Romaian